comparemela.com

Latest Breaking News On - Good research practice - Page 1 : comparemela.com

Research governance & integrity | Research and impact

LSHTM maintains a governance framework comprising a range of principles, policies, procedures and guidelines that regulate our research. This has been developed in accordance with national guidance. Research governance The Research Governance Committee oversees research governance matters across LSHTM, including the policy on Good Research Practice.

Shanghai Genechem Co , Ltd (Genechem) Announces appointment of Dr Eric Rowinsky and Dr Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T

Share this article Share this article SHANGHAI, April 8, 2021 /PRNewswire/ Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel target discovery and development of novel therapeutics, today announced the appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, to its Scientific Advisory Board. Drs. Rowinsky and Hidalgo will bring their strong expertise in translational and clinical development to support Genechem s mission to bring its innovative pipeline to global markets through novel target discovery, early development in China, and global partnership.

Shanghai Genchem Co , Ltd (Genechem) Announces Global Collaboration on Bispecific Antibodies

Shanghai Genchem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies SHANGHAI, April 6, 2021 /PRNewswire/ Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel drug target discovery and development of novel therapeutics, today announced the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a Nasdaq-listed global biopharmaceutical company, to develop and commercialize multiple bi-specific antibodies (BsAb) based on monoclonal antibody developed by Genechem and antibodies selected by I-MAB. This collaboration is the first of many that will leverage Genechem s Good Research Practice (GRP) and CHAMP antibody discovery platform, strong bioinformatic database, as well as strong development expertise of synergistic partners, to deliver globally competitive assets based on innovative targets. We are excited to collaborate with I-Mab, a global leader in Oncology and antibody development, to bring more products to address clin

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.